Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study

por Landen, Jaren W., Andreasen, Niels, Cronenberger, Carol L., Schwartz, Pamela F., Börjesson-Hanson, Anne, Östlund, Henrik, Sattler, Catherine A., Binneman, Brendon, Bednar, Martin M.
Publicado 2017